文献速递膀胱癌与上尿路尿路上皮癌

肌层浸润性膀胱癌新辅助治疗反应评估:临床试验证据对实践的启示

Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.
PubMed 文献 · BJU Int · 2026-08-05

本综述检索截至2025年8月的随机对照试验和前瞻性单臂试验,分析非转移性肌层浸润性膀胱癌新辅助治疗后的反应评估方法。共纳入22项研究(含14项RCT),发现评估方法差异大,CT为RCT最常用模态而膀胱MRI在近期免疫治疗试验中占主导,仅5项研究将再分期与最终病理相关,多参数MRI的nacVI-RADS预测病理完全缓解准确率72%-83%。结论认为反应评估标准化不足,需统一时机、模态和定义。

要点

  • 临床试验中新辅助治疗反应评估方法异质性大,缺乏标准化。
  • CT是RCT中最常用的影像模态,膀胱MRI对局部再分期更准确。
  • 多参数MRI的nacVI-RADS预测病理完全缓解准确率72%-83%。

核心结论

  • MIBC新辅助治疗后的反应评估标准化不足,试验证据支持根治性局部治疗前行横断面影像,CT最成熟但反映试验设计惯例而非诊断优越性。
  • 膀胱MRI对局部再分期更准确,ctDNA等新兴生物标志物需验证,需统一时机、模态和反应定义以实现循证治疗调整。

研究设计与样本

  • 检索PubMed、Embase和ClinicalTrials.gov至2025年8月,纳入非转移性MIBC(cT2-T4a N0-1 M0)的新辅助化疗、化疗免疫或免疫治疗RCT,以及前瞻性单臂化疗免疫或免疫治疗试验。
  • 共纳入22项研究,包括14项RCT;因定义和报告异质性未进行meta分析。

主要发现

  • 多数试验纳入反应评估但方法差异大;CT是RCT最常用模态,膀胱MRI在近期单臂免疫治疗试验中占主导。
  • 评估时机不一致且通常为治疗后,仅两项试验进行 interim 评估;内镜评估集中于保膀胱试验,ctDNA选择性使用。
  • 仅五项研究将再分期与最终病理相关;多参数MRI用nacVI-RADS评分预测病理完全缓解准确率72%-83%;无试验报告新辅助治疗后远处转移的影像准确性。

关键数值与推荐

  • 多参数MRI的nacVI-RADS预测病理完全缓解准确率72%-83%。
  • 仅两项试验进行治疗中 interim 评估。
  • 仅五项研究将再分期与最终病理相关。

临床怎么用

  • 根治性局部治疗前应行横断面影像评估,CT为最成熟模态,膀胱MRI对局部再分期更准确。
  • 新兴生物标志物如ctDNA需进一步验证后方可用于治疗调整。

局限性

  • 因定义和报告异质性未进行meta分析。
  • 无试验报告新辅助治疗后远处转移的影像准确性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To review how response to neoadjuvant therapy (NAT) is assessed in clinical trials of muscle-invasive bladder cancer (MIBC), and to determine whether trial-derived evidence can inform response evaluation in contemporary practice. SUBJECTS/PATIENTS AND METHODS: We searched PubMed, Embase and ClinicalTrials.gov through August 2025 for randomised controlled trials (RCTs) of neoadjuvant chemotherapy, chemo-immunotherapy or immunotherapy in non-metastatic MIBC (cT2-T4a N0-1 M0), and for prospective single-arm chemo-immunotherapy or immunotherapy trials. We extracted data on imaging modality and coverage, endoscopic and biomarker-based assessment, timing, correlation with final pathology and diagnostic accuracy. Given heterogeneity in definitions and reporting, no meta-analysis was performed. RESULTS: We identified 22 studies, including 14 RCTs. Most incorporated response evaluation, yet methods differed widely. Computed tomography (CT) was the most frequent modality in RCTs, whereas bladder magnetic resonance imaging (MRI) predominated in recent single-arm immunotherapy trials. Timing was inconsistent and usually post-treatment; only two trials performed interim assessment. Endoscopic evaluation was concentrated in bladder-preservation trials, and circulating tumour DNA (ctDNA) was used selectively. Only five studies correlated restaging with final pathology; multiparametric MRI scored with nacVI-RADS predicted pathological complete response with 72%-83% accuracy. No trial reported imaging accuracy for distant metastases after NAT. CONCLUSION: Response assessment after NAT in MIBC remains insufficiently standardised. Trial-derived evidence supports cross-sectional imaging before radical local treatment, with CT the most established modality, largely reflecting trial-design conventions and availability rather than demonstrated diagnostic superiority; bladder MRI is more accurate for local restaging. Emerging biomarkers such as ctDNA require validation. Harmonising timing, modalities and response definitions is needed to enable evidence-based treatment adaptation.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Contieri R, van Rhijn BWG, Cathomas R, et al. Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice. BJU Int. 2026. PMID: 42557233. doi:10.1111/bju.70403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。